论文部分内容阅读
目的:研究厄贝沙坦联合吡格列酮对糖尿病肾病(DN)患者尿VEGF水平的影响。方法:选择糖尿病肾病患者60例,根据尿微量白蛋白排泄率(UAER)分为微量白蛋白尿组(30例)和临床蛋白尿组(30例),每组均分为三个亚组,分别采用格列吡嗪(A组)、吡格列酮(B组)和厄贝沙坦+吡格列酮(C组)连续治疗3个月,在治疗第8周、第10周和第12周分别比较各亚组间尿VEGF水平。结果:在治疗第8周、第10周和第12周,C组分别与A组和B组的尿VEGF水平比较,差异均具有统计学意义(P<0.05),C组的临床效果均显著优于A组和B组。结论:DN患者应首选厄贝沙坦+吡格列酮药物治疗,可显著提高临床疗效,延缓病程进展。
Objective: To investigate the effect of irbesartan combined with pioglitazone on urinary VEGF in patients with diabetic nephropathy (DN). Methods: 60 patients with diabetic nephropathy were divided into microalbuminuria group (30 cases) and clinical proteinuria group (30 cases) according to urinary albumin excretion rate (UAER), and each group was divided into three subgroups. The patients were treated with glipizide (group A), pioglitazone (group B) and irbesartan + pioglitazone (group C) for 3 months respectively, and compared with each other at the 8th week, the 10th week and the 12th week Urinary VEGF levels between groups. Results: At the 8th week, the 10th week and the 12th week, the differences of urinary VEGF levels between group C and group A and group B were statistically significant (P <0.05), and the clinical effects of group C were significant Better than A and B group. Conclusion: DN patients should be the first choice of irbesartan + pioglitazone drug therapy, can significantly improve the clinical efficacy and delay the course of progress.